Stock RCKT ROCKET PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Rocket Pharmaceuticals, Inc.

Equities

RCKT

US77313F1066

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
21.32 USD -0.61% Intraday chart for Rocket Pharmaceuticals, Inc. -0.47% -28.86%
May. 29 Rocket Pharmaceuticals' Gene Therapy for Inherited Heart Disease Receives Orphan Drug Designation in Europe MT
May. 16 Transcript : Rocket Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 10:00 AM

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
BU
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy
AQ
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
BU
Rocket Pharmaceuticals: Q1 Earnings Snapshot
AQ
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
BU
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
BU
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
BU
Thinking about buying stock in Ocean Biomedical, CASI Pharmaceuticals, Cardiol Therapeutics, Geron, or Rocket Pharmaceuticals?
PR
Rocket Pharmaceuticals: Q4 Earnings Snapshot
AQ
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
BU
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI for the Treatment of Severe Leukocyte Adhesion Deficiency-I
AQ
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
BU
Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
BU
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
BU
Rocket Pharmaceuticals: Q3 Earnings Snapshot
AQ
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
BU
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene and Cell Therapy
AQ
Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
BU
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 for the Treatment of Severe Leukocyte Adhesion Deficiency-I
AQ
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RCKT Stock
  4. News Rocket Pharmaceuticals, Inc.
  5. Press Releases